UNSPSC 51111901: Asparaginase

This classification denotes a natural antineoplastic product hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1. with the molecular formula C1377H2208N382O442S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4FQ3CKY5R, chemically known as E. coli L-asparagine amidohydrolase but generally known as asparaginase. European Medicines Agency schedules asparaginase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12950MIG.

World Health Organization schedules asparaginase in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ASPARAGINASE remains the US FDA Preferred Term for this commodity.

UNSPSC 51111901 Asparaginase, a Commodity code, addresses pharmaceutical procurement by state and local government health agencies and employee health plans seeking specific therapeutic medications. The code designates a single-product line—asparaginase, a chemotherapy agent used primarily in treatment of acute lymphoblastic leukemia and other malignancies. State and local health agencies, Medicaid programs, corrections departments, and employee health plans acquire asparaginase through traditional pharmacy benefit managers, group purchasing organizations, and direct manufacturer relationships to support clinical care in hospital systems, outpatient oncology centers, and institutional settings. Solicitations under this code typically structure pharmaceutical acquisition through fixed-price contracts, direct-to-manufacturer arrangements, rebate-based pricing models, or outcomes-based agreements negotiated on a net-pricing foundation.

The Texas Health and Human Services Commission issued RFI No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to solicit vendor capabilities and market intelligence regarding direct-to-manufacturer prescription programs under its Therapeutic Pharmacy Initiative. The RFI targets vendors experienced with direct contracting for self-insured employers and health plans in both private and government sectors, requesting information on capacity to negotiate contracts based on net pricing models without rebates, implement value-based or outcomes-based agreements, and fulfill volume requirements outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The RFI represents an exploratory procurement phase designed to inform the state's future formal competitive solicitation strategy. Recent activity under this code remains limited; no other state or local opportunities are documented in the source block, and no award values, budget ranges, or defined set-asides are present at this stage.